River Road Asset Management LLC Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

River Road Asset Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 12.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 602,628 shares of the biopharmaceutical company’s stock after selling 82,135 shares during the quarter. River Road Asset Management LLC’s holdings in Pfizer were worth $23,599,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Usca Ria LLC lifted its position in Pfizer by 11.6% during the second quarter. Usca Ria LLC now owns 504,526 shares of the biopharmaceutical company’s stock valued at $19,757,000 after buying an additional 52,362 shares during the period. Cito Capital Group LLC increased its holdings in shares of Pfizer by 59.6% during the first quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock valued at $1,407,000 after acquiring an additional 14,500 shares in the last quarter. Advisor Group Holdings Inc. increased its holdings in shares of Pfizer by 4.4% during the second quarter. Advisor Group Holdings Inc. now owns 2,090,666 shares of the biopharmaceutical company’s stock valued at $81,925,000 after acquiring an additional 88,276 shares in the last quarter. Guggenheim Capital LLC increased its holdings in shares of Pfizer by 2.8% during the first quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock valued at $52,950,000 after acquiring an additional 40,497 shares in the last quarter. Finally, Carolina Wealth Advisors LLC increased its holdings in shares of Pfizer by 7.1% during the second quarter. Carolina Wealth Advisors LLC now owns 112,745 shares of the biopharmaceutical company’s stock valued at $4,415,000 after acquiring an additional 7,456 shares in the last quarter. 64.93% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:PFE opened at $44.51 on Wednesday. The stock has a market capitalization of $249.55 billion, a price-to-earnings ratio of 19.19, a PEG ratio of 1.58 and a beta of 0.74. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 1.37. The stock’s 50-day simple moving average is $44.74 and its two-hundred day simple moving average is $40.35. Pfizer Inc. has a 52-week low of $33.36 and a 52-week high of $51.86.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.10. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. The business had revenue of $18.98 billion for the quarter, compared to analysts’ expectations of $17.54 billion. During the same period last year, the firm posted $0.78 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.50%. Pfizer’s payout ratio is currently 70.27%.

In related news, SVP Jennifer B. Damico sold 1,661 shares of the business’s stock in a transaction that occurred on Friday, August 13th. The stock was sold at an average price of $48.30, for a total value of $80,226.30. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, July 30th. The stock was sold at an average price of $42.86, for a total value of $107,150.00. Following the completion of the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at $489,889.80. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.

PFE has been the subject of several analyst reports. Royal Bank of Canada set a $44.00 price target on Pfizer in a report on Thursday, July 29th. JPMorgan Chase & Co. raised their price target on Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a report on Monday. Morgan Stanley raised their price target on Pfizer from $42.00 to $45.00 and gave the company an “equal weight” rating in a report on Thursday, July 29th. Mizuho lifted their price objective on Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Friday, July 30th. Finally, SVB Leerink reiterated a “hold” rating and issued a $49.00 price objective on shares of Pfizer in a report on Tuesday. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $42.77.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: How Buying a Call Option Works

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.